More news on: Faculty News, Prof. Erika Lietzan

Professor Lietzan Publishes Article Critiquing Drug Legislation Pending in Congress

September 29th, 2016

Erika Lietzan

Professor Lietzan has published an article in the Federalist Society Review critiquing drug legislation that is currently pending in the U.S. Senate. The “CREATES Act” would require innovative drug companies to sell their products to their competitors and would require these companies to share with these same competitors the use and distribution arrangements they developed to manage the risks of the products.

Professor Lietzan, who specializes in FDA regulation of drugs and biologics as well as intellectual property, provides a deeper look at pharmaceutical risk management, the issues that this legislation purports to address, and the real impact the legislation would have.

Tags: , ,